EUCTR2005-006168-71-IT进行中（未招募）不适用
Phase II study with gemcitabine/docetaxel first line in women with metastatic breast cancer - SF- 2Gem/tax
A.S.L. 20 个研究点目标入组 70 人开始时间: 2006年6月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •metastatic breast cancer adjuvant treatment withantracicline and treatment with taxans ended at least one year before years 18 and 75 performance status 2 liver and hepatic normal functionality normal cardiac function informed consent written woman fertile age must use contraceptive to warrant coverage greater than the 99
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •patients treated with chemioterapy for metastatic breast cancer previous neoplas except cutaneous and cervix in situ carcinoma pregnancy brain metastasis radioterapy on single valuable lesion positivity 3 for HER2/neu with IHC or FISH psichiatrics disease to compromise written informed consens or compliance of the patient patients with only bone metastasis
研究者
相似试验
进行中（未招募）
不适用
Phase II study with gemcitabine/docetaxel fist line in women with metastatic breast cancer. - SF2gem/taxOncologic patients only.MedDRA version: 6.1Level: PTClassification code 10055113EUCTR2006-000165-10-ITA.S.L. 2 SAVONA70
进行中（未招募）
1 期
A fase I/II trial with docetaxel and gemcitabine in hormone refractory prostate cancerHormone fractory prostate cancerEUCTR2004-002353-31-DKOrganisation name was not entered60
招募中
2 期
Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomasadvanced bone and soft tissue sarcomasJPRN-UMIN000031004Kobe University20
招募中
2 期
GD therapy for advanced sarcomasadvanced pretreated bone and soft tissue sarcomasJPRN-jRCTs051180042Hara Hitomi20
招募中
2 期
Study of gemcitabine docetaxel in synovial sarcoma in relapsed metastatic settingCTRI/2020/02/023612Department of Medical Oncology